Y Intercept Hong Kong Ltd Sells 41,220 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Key Points

• Y Intercept Hong Kong Ltd has decreased its holdings in Genmab A/S Sponsored ADR by 55.9%, selling 41,220 shares and now owning 32,476 shares valued at $636,000.
• Several institutional investors, including Deep Track Capital LP and Renaissance Technologies LLC, have made significant modifications to their positions in Genmab A/S during the fourth quarter.
• Analyst ratings for Genmab A/S vary, with HC Wainwright maintaining a "buy" rating with a new price target of $37.00, while other analysts cut price targets, indicating diverse sentiment on the stock's prospects.

Y Intercept Hong Kong Ltd trimmed its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 55.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,476 shares of the company's stock after selling 41,220 shares during the period. Y Intercept Hong Kong Ltd's holdings in Genmab A/S were worth $636,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in Genmab A/S in the fourth quarter worth about $2,463,000. GAMMA Investing LLC raised its stake in Genmab A/S by 1,465.3% in the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock worth $656,000 after buying an additional 31,343 shares in the last quarter. Northern Trust Corp raised its stake in Genmab A/S by 18.8% in the fourth quarter. Northern Trust Corp now owns 599,381 shares of the company's stock worth $12,509,000 after buying an additional 94,858 shares in the last quarter. LPL Financial LLC raised its stake in Genmab A/S by 3.3% in the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company's stock worth $4,079,000 after buying an additional 6,288 shares in the last quarter. Finally, Sei Investments Co. raised its stake in Genmab A/S by 55.2% in the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company's stock worth $1,205,000 after buying an additional 20,525 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB traded down $0.33 during trading on Wednesday, reaching $22.27. 709,406 shares of the stock traded hands, compared to its average volume of 1,036,941. The stock has a 50-day moving average of $21.62 and a two-hundred day moving average of $20.83. Genmab A/S Sponsored ADR has a 52-week low of $17.24 and a 52-week high of $28.56. The stock has a market cap of $14.29 billion, a P/E ratio of 12.65, a price-to-earnings-growth ratio of 6.87 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The firm had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. Sell-side analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

GMAB has been the subject of a number of research reports. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday. Truist Financial upped their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. HC Wainwright restated a "buy" rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.